GAPNA is a name chosen to reflect the diversity of our current and potential members, all who are interested in providing the highest quality of care to older adults.

We are the only advanced practice nursing organization that focuses on older adults, the fastest growing segment of the population.

View complete details about the GAPNA Strategic Partners Program.

If you would like to discuss your involvement and more details, please contact Miriam I. Martin, Marketing Specialist, at 856-256-2374.

GAPNA thanks our current Strategic Partners for their support of our organization.

Platinum Strategic Partners

ACADIA

ACADIA Pharmaceuticals
12830 El Camino Real
Suite 400
San Diego, CA 92130
www.acadia-pharm.com

As a leader in developing and commercializing innovative therapies for central nervous system disorders ACADIA Pharmaceuticals is committed to improving the lives of patients..


Avanir

Avanir Pharmaceuticals
30 Enterprise, Suite 400
Aliso Viejo, CA 92656
949-389-6700
www.avanir.com

Avanir Pharmaceuticals is a pharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need.


Eisai

Eisai
6611 Tributary Street, Suite 1
Baltimore, MD  21224
410-631-6300
www.eisai.com

At Eisai Inc., human health care (hhc) is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.

Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at www.eisai.com/US and follow us on Twitter and LinkedIn.


Gold Strategic Partners

Neurocrine Biosciences Inc.

Neurocrine Biosciences Inc.
12780 El Camino Real
San Diego, CA 92130
858-617-7600
www.neurocrine.com

Neurology and Endocrinology Research and Therapy | Neurocrine Biosciences

Neurocrine discovers and develops pharmaceutical through its R&D platform, focused on neurological and endocrine based diseases and disorders. Learn more.


PsychU

PsychU
2440 Research Blvd
Rockville, MD 20850
info@psychu.org
www.PsychU.org

PsychU is a community and comprehensive resource library for mental health. Our over 73,000 members share one simple belief: Enhanced information, increased collaboration, and ongoing discussion will lead to improved mental health care and patient outcomes for individuals with mental illnesses. Access thousands of mental health resources, webinars, live events and more, for free! Join us in improving mental health care… together.


Strategic Partners

Genentech

Genentech
1 DNA Way
South San Francisco, CA 94080
www.gene.com

Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for more than 40 years.

Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Our transformational discoveries include the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis.


Xeris

Xeris Pharmaceuticals, Inc.
180 N. Lasalle Street, Suite 1600
Chicago, IL  60601
844-445-5704
www.xerispharma.com

 

Xeris Pharmaceuticals, Inc., the maker of Gvoke Hypopen®, is dedicated to unlocking the potential of glucagon. We believe that easier-to-use medicines can have a profound impact on the lives of patients and their families. That is why our first products to market are liquid glucagon, but that is just the beginning. We are also studying how our formulation technology can impact patients with other conditions. We have a persistent drive to pursue advancements that have the potential to change lives. Get to know us and see how our technology is unlocking the potential of today’s medicines at www.xerispharma.com.